Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 361 to 370 of 903

TitleReference numberPublishedLast updated
Venetoclax for treating chronic lymphocytic leukaemiaTA796
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Diroximel fumarate for treating relapsing–remitting multiple sclerosisTA794
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
Filgotinib for treating moderately to severely active ulcerative colitisTA792
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)TA790
Romosozumab for treating severe osteoporosisTA791
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788

Results per page

  1. 10
  2. 25
  3. 50
  4. All